Sunesis Pharmaceuticals (SNSS) & Its Competitors Financial Survey
Sunesis Pharmaceuticals (NASDAQ: SNSS) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Sunesis Pharmaceuticals to similar businesses based on the strength of its earnings, analyst recommendations, valuation, risk, dividends, profitability and institutional ownership.
Institutional & Insider Ownership
38.4% of Sunesis Pharmaceuticals shares are held by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Sunesis Pharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sunesis Pharmaceuticals||$2.54 million||-$38.02 million||-1.42|
|Sunesis Pharmaceuticals Competitors||$219.08 million||-$39.69 million||-68.21|
Sunesis Pharmaceuticals’ rivals have higher revenue, but lower earnings than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Sunesis Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Sunesis Pharmaceuticals’ rivals have a beta of 1.58, suggesting that their average stock price is 58% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Sunesis Pharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sunesis Pharmaceuticals Competitors||537||2452||6637||125||2.65|
Sunesis Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 61.29%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.14%. Given Sunesis Pharmaceuticals’ higher probable upside, analysts plainly believe Sunesis Pharmaceuticals is more favorable than its rivals.
This table compares Sunesis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sunesis Pharmaceuticals Competitors||-3,258.67%||-518.74%||-38.46%|
Sunesis Pharmaceuticals rivals beat Sunesis Pharmaceuticals on 8 of the 12 factors compared.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.